Observational StudyNCT05135013
The Association of Hormonal Intake and Demographic Factors With Breast Cancer Risk. An Egyptian Case-controlled Study
An observational study of Observational Study, run by NewGiza University.
Trial summary
The aim of the current study is to investigate the association between hormonal intake, occupational and demographic factors, and the risk of breast cancer (BC) among Egyptian females. Read more about this study
- Who is it for?
- Ages 18 to 70 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Observational Study
- What is being tested?
- Dydrogesterone Tablets, Norethisterone acetate, Ethinyl estradiol, Drospirenone and ethinyl estradiol
- Type of treatment
- Pill or oral medicine
- How many people
- 200 participants
- Where
- No sites listed yet
- Study dates
- 16 Nov 2021to 31 Mar 2022
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 70 years
- Women only
- Healthy volunteers accepted
- Adult, Older adult
Study population: Eligible candidates will be stratified as cases or matched controls as follows: 1. Cases (100) are those eligible patients who were diagnosed with histopathologically confirmed breast cancer and were during the past 2 years to 2021 (2019-2020). 2. Matched controls (100) are those participants presenting to the screening clinic and were not diagnosed with breast cancer during the past 2 years to 2021 (2019-2020). Candidates are to be of same range of age (+/-3 years); and similar visiting period (+/-2 months). All controls were confirmed as having no diagnosis of breast cancer, with negative findings on physical breast examination, and breast sono-mammographic screening.
Who may be able to join
- Age > 18 and < 70
Who cannot join
- Diagnosed with other concurrent malignancies.
- A prior history of another cancer.
Trial locations and contacts
No sites are listed yet.
About this study
The aim of the current study is to investigate the association between hormonal intake, occupational and demographic factors, and the risk of breast cancer (BC) among Egyptian females.
Read the detailed description
Methodology Design. A case-controlled study.
Setting. Breast cancer clinic and breast cancer screening unit at clinical oncology department, Ain Shams University hospital
Participants.
All cases who will be screened from the BC clinic and the BC screening unit will be assessed for eligibility according to the following inclusion \& exclusion criteria:
Inclusion criteria
Age > 18 and < 70
Exclusion criteria
- Diagnosed with other concurrent malignancies.
- A prior history of another cancer.
Eligible candidates will be stratified as cases or matched controls as follows:
- Cases (100) are those eligible patients who were diagnosed with histopathologically confirmed breast cancer and were during the past 2 years to 2021 (2019-2020).
- Matched controls (100) are those participants presenting to the screening clinic and were not diagnosed with breast cancer during the past 2 years to 2021 (2019-2020). Candidates are to be of same range of age (+/-3 years); and similar visiting period (+/-2 months). All controls were confirmed as having no diagnosis of breast cancer, with negative findings on physical breast examination, and breast sono-mammographic screening.
Ethical consideration. The protocol will be approved by the ethical committee of NGU and the Clinical Oncology department ASU. The study will be registered at clinicaltrials.gov
Methods.
Data collection for both groups will be done through reviewing of the participants' medical records retrospectively Data collection will include the following data:
- Demographic data: name, age, sex, residence
- Anthropometric data: height, weight, waist \& hip circumference \& waist to hip ratio and BMI calculation
- Female \& menopausal status, age at menarche
- Medical history \& comorbidity (CVS, DM 1 or 2, HTN)
- Family history of other cancers, diabetes
- Occupational history
- Social history: smoking, recreational drug use, marital status, nulliparity/multi-parity and lactation
- Dietary habits and diet composition
- Lifestyle habits and degree of regular activity (sedentary, active, etc.)
- History of hormonal use as follows:
- Reason for hormonal use: contraception, fertility promotion, PCOS
- Duration of hormonal use
- Type of hormonal drug used: dose, hormone type, route of administration
- Breast cancer classification:
- - Type of pathology - 2- Molecular classification (ER, PR, Her2 receptors status) 3- Staging of BC.
Statistical analysis The frequency distribution of the parameters will be assessed. Parametric data will be presented as mean \& standard deviation, while non parametric data will be presented as median \& IQR. All data will be analyzed using the appropriate statistical test. Proportions will be presented using number \& proportion and will be assessed by the Chi square.
Multiple logistic regression analysis will be used to calculate odds ratios (OR) and corresponding 95% confidence intervals (CI) for the various studied factors in relation to breast cancer occurrence \& subtypes.
Moreover, the effect of the combined significant factors to the risk of breast cancer development will be evaluated.
- Conditions
- Observational Study
- Being tested
- Dydrogesterone Tablets, Norethisterone acetate, Ethinyl estradiol, Drospirenone and ethinyl estradiol
- Keywords
- Hormonal Intake, Breast Cancer Risk, Demographic Factors
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Dydrogesterone Tablets, Norethisterone acetate, Ethinyl estradiol, Drospirenone and ethinyl estradiolDrug
History of hormonal use as follows:
- Reason for hormonal use: contraception, fertility promotion, Polycystic ovary syndrome (PCOS)
- Duration of hormonal use
- Type of hormonal drug used: dose, hormone type, route of administration
| Study group | Role | What they receive |
|---|---|---|
| Cases | 1.Cases (100) are those eligible patients who were diagnosed with histopathologically confirmed breast cancer and were during the past 2 years to 2021 (2019-2020). Receives: Drug: Dydrogesterone Tablets, Norethisterone acetate, Ethinyl estradiol, Drospirenone and ethinyl estradiol | |
| Matched Controls | 2. Matched controls (100) are those participants presenting to the screening clinic and were not diagnosed with breast cancer during the past 2 years to 2021 (2019-2020). Candidates are to be of same range of age (+/-3 years); and similar visiting period (+/-2 months). All controls were confirmed as having no diagnosis of breast cancer, with negative findings on physical breast examination, and breast sono-mammographic screening. Receives: Drug: Dydrogesterone Tablets, Norethisterone acetate, Ethinyl estradiol, Drospirenone and ethinyl estradiol |
What is being measured
The primary outcome is the main question the study is designed to answer.
Confirmed Breast Cancer Patients
Patients who were diagnosed with histopathologically confirmed breast cancer and were during the past 2 years to 2021 (2019-2020).
Measured: During the past 2 years to 2021 (2019-2020).
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Nov 2021
- Study start16 Nov 2021 (estimated)
- Primary completion31 Jan 2022 (estimated)
- Study completion31 Mar 2022 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Observational StudyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Retrospective
- Enrolment
- 200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- NewGiza University
- Sponsor type
- University, hospital or other
- Collaborators
- Ain Shams University
- Responsible party
- Principal investigator, Nermeen Ashoush, NewGiza University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05135013
- Sponsor's protocol ID
- NewGiza University Protocol 1
- Status last verified
- Nov 2021
- First submitted
- 16 Nov 2021
- Last updated
- 26 Nov 2021
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 26 Nov 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Association of Hormonal Intake and Demographic Factors With Breast Cancer Risk. An Egyptian Case-controlled Study
- ClinicalTrials.gov ID
- NCT05135013
- Acronym / sponsor ID
- NewGiza University Protocol 1
- Conditions
- Observational Study
- Keywords
- Hormonal Intake, Breast Cancer Risk, Demographic Factors
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 200 participants (estimated)
- Lead sponsor
- NewGiza UniversityUniversity, hospital or other
- Collaborators
- Ain Shams University
- Study start
- 16 Nov 2021 (estimated)
- Primary completion
- 31 Jan 2022 (estimated)
- Study completion
- 31 Mar 2022 (estimated)
- First posted
- 26 Nov 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of the current study is to investigate the association between hormonal intake, occupational and demographic factors, and the risk of breast cancer (BC) among Egyptian females.
Detailed description
Methodology Design. A case-controlled study.
Setting. Breast cancer clinic and breast cancer screening unit at clinical oncology department, Ain Shams University hospital
Participants.
All cases who will be screened from the BC clinic and the BC screening unit will be assessed for eligibility according to the following inclusion \& exclusion criteria:
Inclusion criteria
Age > 18 and < 70
Exclusion criteria
- Diagnosed with other concurrent malignancies.
- A prior history of another cancer.
Eligible candidates will be stratified as cases or matched controls as follows:
- Cases (100) are those eligible patients who were diagnosed with histopathologically confirmed breast cancer and were during the past 2 years to 2021 (2019-2020).
- Matched controls (100) are those participants presenting to the screening clinic and were not diagnosed with breast cancer during the past 2 years to 2021 (2019-2020). Candidates are to be of same range of age (+/-3 years); and similar visiting period (+/-2 months). All controls were confirmed as having no diagnosis of breast cancer, with negative findings on physical breast examination, and breast sono-mammographic screening.
Ethical consideration. The protocol will be approved by the ethical committee of NGU and the Clinical Oncology department ASU. The study will be registered at clinicaltrials.gov
Methods.
Data collection for both groups will be done through reviewing of the participants' medical records retrospectively Data collection will include the following data:
- Demographic data: name, age, sex, residence
- Anthropometric data: height, weight, waist \& hip circumference \& waist to hip ratio and BMI calculation
- Female \& menopausal status, age at menarche
- Medical history \& comorbidity (CVS, DM 1 or 2, HTN)
- Family history of other cancers, diabetes
- Occupational history
- Social history: smoking, recreational drug use, marital status, nulliparity/multi-parity and lactation
- Dietary habits and diet composition
- Lifestyle habits and degree of regular activity (sedentary, active, etc.)
- History of hormonal use as follows:
- Reason for hormonal use: contraception, fertility promotion, PCOS
- Duration of hormonal use
- Type of hormonal drug used: dose, hormone type, route of administration
- Breast cancer classification:
- - Type of pathology - 2- Molecular classification (ER, PR, Her2 receptors status) 3- Staging of BC.
Statistical analysis The frequency distribution of the parameters will be assessed. Parametric data will be presented as mean \& standard deviation, while non parametric data will be presented as median \& IQR. All data will be analyzed using the appropriate statistical test. Proportions will be presented using number \& proportion and will be assessed by the Chi square.
Multiple logistic regression analysis will be used to calculate odds ratios (OR) and corresponding 95% confidence intervals (CI) for the various studied factors in relation to breast cancer occurrence \& subtypes.
Moreover, the effect of the combined significant factors to the risk of breast cancer development will be evaluated.
Study design
- Observational model
- Case-control
- Time perspective
- Retrospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Cases | – | Drug: Dydrogesterone Tablets, Norethisterone acetate, Ethinyl estradiol, Drospirenone and ethinyl estradiol1.Cases (100) are those eligible patients who were diagnosed with histopathologically confirmed breast cancer and were during the past 2 years to 2021 (2019-2020). |
| Matched Controls | – | Drug: Dydrogesterone Tablets, Norethisterone acetate, Ethinyl estradiol, Drospirenone and ethinyl estradiol2. Matched controls (100) are those participants presenting to the screening clinic and were not diagnosed with breast cancer during the past 2 years to 2021 (2019-2020). Candidates are to be of same range of age (+/-3 years); and similar visiting period (+/-2 months). All controls were confirmed as having no diagnosis of breast cancer, with negative findings on physical breast examination, and breast sono-mammographic screening. |
Who may qualify
- Ages
- 18 to 70 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Eligible candidates will be stratified as cases or matched controls as follows: 1. Cases (100) are those eligible patients who were diagnosed with histopathologically confirmed breast cancer and were during the past 2 years to 2021 (2019-2020). 2. Matched controls (100) are those participants presenting to the screening clinic and were not diagnosed with breast cancer during the past 2 years to 2021 (2019-2020). Candidates are to be of same range of age (+/-3 years); and similar visiting period (+/-2 months). All controls were confirmed as having no diagnosis of breast cancer, with negative findings on physical breast examination, and breast sono-mammographic screening.
Key inclusion criteria (1 listed)
- Age > 18 and < 70
Key exclusion criteria (2 listed)
- Diagnosed with other concurrent malignancies.
- A prior history of another cancer.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Dydrogesterone Tablets, Norethisterone acetate, Ethinyl estradiol, Drospirenone and ethinyl estradiolHistory of hormonal use as follows: 1. Reason for hormonal use: contraception, fertility promotion, Polycystic ovary syndrome (PCOS) 2. Duration of hormonal use 3. Type of hormonal drug used: dose, hormone type, route of administration | Drug | Cases, Matched Controls |
Primary outcome
Confirmed Breast Cancer Patients
Time frame: During the past 2 years to 2021 (2019-2020).
Patients who were diagnosed with histopathologically confirmed breast cancer and were during the past 2 years to 2021 (2019-2020).
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Nov 2021.
- Individual participant dataSharing planned: Undecided
Related trials for Observational Study
RecruitingObservational study
Pre- and On-treatment Multi-omics Profiling of Locally Advanced Rectal Cancer
Rectal Neoplasms
Not yet recruitingObservational study
Postural Control and Balance Performance in Patients With Carpal Tunnel Syndrome
Carpal Tunnel Syndrome (CTS), Postural Assessment
Enrolling by invitationObservational study
Early Molecular Biomarkers for Differentiating Parkinsonian Syndromes
PARKINSON DISEASE (Disorder), Atypical Parkinsonism
Enrolling by invitationObservational study
Using Smartwatches to Monitor Smoking in Real-life Situations
Smoking
RecruitingObservational study
Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors
Malignant Solid Neoplasm
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Questions about this trial
What is this clinical trial studying?
An observational study of Observational Study, run by NewGiza University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 26 Nov 2021. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Nermeen Ashoush, PhD (+201001809397, nermeen.ashoush@ngu.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Confirmed Breast Cancer Patients (time frame: During the past 2 years to 2021 (2019-2020).). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Nov 2021.